Why the study?
Does low-dose systemic tPA improve right ventricular function, in-hospital mortality, and bleeding complications compared to standard anticoagulation in patients with intermediate-high risk pulmonary embolism?
Does low-dose systemic tPA improve right ventricular function, in-hospital mortality, and bleeding complications compared to standard anticoagulation in patients with intermediate-high risk pulmonary embolism?
Low-dose systemic tPA improves right ventricular function and may reduce bleeding complications compared to standard anticoagulation in patients with intermediate-high risk pulmonary embolism.
Answers are grounded in this paper and cite their sources.
May support low-dose tPA for PASP/RV improvement in intermediate-high risk PE; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative. However, studies directly comparing the efficacy and safety of low-dose tPA to AC are lacking in this patient population. OBJECTIVES: The aim of this study was to retrospectively compare the efficacy and safety of low-dose tPA, compared to AC alone in regards to right ventricular function, in-hospital mortality and bleeding complications in patients presenting with intermediate-high risk PE. METHODS: This is a single-center, retrospective cohort trial conducted at a university hospital. A total of 148 patients were screened, and 88 patients qualified for this study. The primary endpoints were changes in right ventricular function on echocardiogram in 24 hours, in-hospital mortality, and major bleeding complications. RESULTS: Eighty-eight consecutive patients with intermediate high-risk PE were included. Twenty- six patients (29.5%) received low-dose systemic tPA administered via intravenous infusion, and 62 patients (70.4%) received standard full-dose anticoagulation. There were no significant differences in baseline vital signs or PESI scores between the low-dose tPA and the AC group. Patients in the low-dose tPA group had worse RV function and higher troponin levels at baseline but showed significant improvement in all RV parameters assessed during the 24-hour follow-up. In comparison, there was no significant improvement in RV function in the AC group. There were more bleeding events in the AC group. LOS was shorter in the low-dose tPA group. CONCLUSION: Treatment with low-dose prolonged infusion of tPA may be an effective and safe therapy in patients with intermediate-risk PE. Compared to AC, low-dose tPA was effective in decreasing PASP and restoration of RV function.
No takes yet. Share an insight, caveat, or question.
Rosa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: